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Background: Plerixafor with granulocyte stimulating factor
(G-CSF) is effective for Peripheral Blood CD34+ stem cell
(PBSC) mobilization in patients with poor marrow reserve.
Plerixafor labeling requires administration 11 hours (hrs)
before apheresis. Studies show administration of Plerixafor +
G-CSF results in peak PBSC concentration 10-14 hrs later.
Limited data is available on PBSC count beyond the 14 hr
period, though a recent study showed successful mobiliza-
tion 17 hrs after administration. This allows for a convenient
afternoon dosing for apheresis the next morning. There is no
data on the effect of Plerixafor on PBSC collection beyond the
day after drug administration.
Methods: We studied PBSC collection in seven patients with
diagnosis of Multiple Myeloma(5) or NHL (2) who received
Plerixafor for low PBSC count < 10/ml (5) or low PBSC
collection despite CD34+ count >10/ml(2). All patients had
been heavily pretreated with 3 chemotherapy regimens (6/
7) or had received chemotherapy associated with high risk of
mobilization failure (1/7). Mobilization regimen consisted of
G-CSF (1), Cyclophosphamide + GCSF (1) or combination
chemotherapy + GCSF (5). Patients failing collection received
Plerixafor 0.24mg/kg s/c with G-CSF at 10mcg/kg s/c daily
with apheresis 11- 16 hrs later till target PBSC count was
obtained. Patients then received G-CSF at 10mcg/kg s/c
without Plerixafor and underwent another apheresis the
following day 35-40 hrs after administration of last dose of
Plerixafor.
Results: Patients received Plerixafor beginning day 15-19 in
patients receiving combination chemotherapy, day 14 in
patient receiving Cyclophosphamide and day 6 in patient
receiving G-CSF alone. Total number of Plerixafor dose(s)
received for each patient was 1 to 4 (median 3). Average daily
collection 11-16 hrs post Plerixafor + G-CSF for individual
patients ranged from 0.49 to 4.21 PBSC/kg/day with a mean
of 1.20 PBSC/kg/day. PBSC collection 11-16 hrs after the last
dose of Plerixafor + GCSF ranged from 0.37 to 4.21 PBSC/kg
(mean 2.01). Collection 35-40 hrs post last dose of Plerixafor
ranged from 0.41 to 5.25 PBSC /kg (mean 2.35). All patientsFig 1. Genotype directed initial Voriconazole dosingcollected more PBSC in the 35-40 hr time frame compared to
the 11-16 hr period. The increment in collection in the 35-40
hr period was from 0.01 PBSC/kg to 1.04 PBSC/kg with a
mean increase of 0.34 PBSC/kg. The patient who received G-
CSF alone with no chemotherapy, collections 11 hrs and 35
hrs post Plerixafor were 0.73 PBSC/kg and 1.40 PBSC/kg
respectively.
Discussion: Successful hematopoietic stem cell mobilization
with G-CSF alone was obtained 35-40 hrs beyond last dose of
Plerixafor administration. There is need for further phar-
macodynamic studies on Plerixafor and CD34+ cell count
beyond the conventional 11-14 hr window. Temporal ad-
justments in Plerixafor administration can result in signiﬁ-
cant cost savings and improved convenience in PBSC
mobilization.115
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Background: Invasive fungal infections are a signiﬁcant
cause of morbidity and mortality in recipients of hemato-
poietic cell transplantation (HSCT), warranting antifungal
prophylaxis as a standard of care in these patients. Due to its
broad spectrum activity and multiple available dosage
forms, voriconazole remains one of the commonly usedand subsequent dose adjustment algorithm
Figure 2.
Abstracts / Biol Blood Marrow Transplant 20 (2014) S91eS103S100agents in this setting. Voriconazole is known to have wide
inter- and intra-patient variability in levels. Additionally
these levels are affected by a common CYP450 poly-
morphism, CYP450-2C19. We have previously shown that
voriconazole dosing of 5 mg/kg/dose every 12 hours is not
sufﬁcient to achieve target prophylactic goal levels in pe-
diatric patients undergoing HSCT, leaving these patients
susceptible to fungal infections during their vulnerable post
HSCT period. The aim of this follow-up study was to
determine if genotype directed initial voriconazole dosing
and subsequent adjustment based on our new algorithm
(Fig 1) will decrease time to desired target range for fungal
prophylaxis. A secondary aim was to determine if the inci-
dence of adverse effects will increase secondary to using
higher initial doses and larger dose adjustments. Here we
report our experience using genotype and new algorithm
directed initial and subsequent dosing of voriconazole
respectively to optimize antifungal prophylactic regimen
for this high risk population.
Methods: All patients undergoing HSCT at Cincinnati Chil-
dren’s Hospital Medical Center who received voriconazole
anti-fungal prophylaxis between June 2013 and September
2013 were followed prospectively. All patients were geno-
typed for CYP2C19 polymorphisms which are known to alter
voriconazole metabolism (normal, fast or slow metabo-
lizers). Initial voriconazole dose was decided based on the
patient’s genotype and changes in dose were made as shown
in Fig 1 to achieve concentrations within the target range of 1
mcg/mL to 5 mcg/mL. All patients were monitored for com-
mon voriconazole side effects.
Results: A total of 20 patients, aged 10 months to 26 years
received voriconazole prophylaxis based on their CYP450-
2C19 genotype and according to the above algorithm. The
median time to reach the target level was 8 days (range 2-47
days). This was signiﬁcantly improved compared to time to
target level in our pilot study (median 30 days range 3-67 days)
(p< 0.001) (ﬁgure 2). There were no adverse effects attributed
to voriconazole therapy. There was one breakthrough fungal
infection, despite voriconazole levels within the target range,
from Candida albicans resistant to voriconazole.
Conclusions: Our results show that CYP450-2C19 genotype
directed initial dosing and subsequent dose adjustments
as per the above algorithm, can successfully achieveprophylactic voriconazole target levels in pediatric patients
undergoing HSCT.TRANSPLANT NURSING CLINICAL116
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Topic Signiﬁcance & Study Purpose/Background/
Rationale: Stem cell transplant (SCT) is a treatment used
for pediatric patients with bothmalignant and nonmalignant
diseases. SCT can offer a cure for these patients; however, the
intensive therapy can affect nutritional status due tomultiple
factors impacting caloric needs, including nausea, mucositis,
diarrhea, fever, infection and graft versus host disease.
Managing the complex nutritional needs is challenging in
this pediatric population. Every patient receives a nutrition
consult during admission and most receive PN but long term
assessment of nutritional status is not routinely done.
Methods, Intervention, & Analysis: A retrospective chart
review was carried out at Dana Farber/Boston Children’s
Hospital in consecutive patients who underwent a matched
related donor SCT for treatment of hemoglobinopathy (sickle
cell and thalassemia) (n¼12) or acute leukemia (n¼46) be-
tween the years 2007-2012. Z-scores were used to indicate
the distance from the population mean by standard de-
viations: positive scores being above the mean and negative
scores being below the mean. The weight z-scores for each
patient were recorded at different intervals: the day of
transplant (day 0), day 100 and one year post transplant.
These values were compared to determine the longitudinal
impact of SCT on nutritional status.
Findings & Interpretation: Four different groups were
deﬁned to characterize the change in weight z-score from
day 0 to day 100 and day 0 to one year: negative z-score at
day 0 to negative at day 100 or one year (negjneg), negative
at day 0 to positive at day 100 or one year (negjpos), pos-
itive at day 0 to negative at day 100 or one year (posjneg),
and positive at day 0 to positive at day 100 or one year
(posjpos). Of the 30 leukemia patients who were positive
(+) pre SCT, over half (18) were (+) at day 100 and of the 23
patients followed until one year, 18/23 remained (+). For
nonmalignant patients, 3 of the 4 that were (+) at day
0 were (+) at day 100 and of the 3 patients followed until
one year, 3/3 remained (+). Those patients who were well
nourished at day 0 as assessed by (+) z-scores tend to
maintain this status at both early and late post SCT time
points.
Discussion & Implications: SCT is known to impact nutri-
tion but the degree and duration of that impact is not well
understood in the pediatric allogeneic population. We have
shown that pre-SCT nutritional status, whether a patient is
appropriately nourished or malnourished, makes a major
contribution to nutritional status both short term (day 100)
and long term (one year) after transplant. Overall, well
nourished patients with leukemia or hemoglobinopathies
tend to maintain their nutritional status, whereas malnour-
ished patients do not easily make nutritional gains. Thus
dedicated efforts must be made to the vulnerable group of
patients beginning the transplant process in a poor nutri-
tional state to optimize transplant outcome.
